Across sources, the central point is that Africa’s disease burden is high but people from the region are frequently underrepresented in clinical trials that generate evidence for modern medicine. The Conversation notes that Africa accounts for about a quarter of the global disease burden, yet randomized controlled trials often include few participants from African settings. This imbalance means that treatment effects, safety profiles, and other clinically relevant outcomes may not be fully established for African populations. The reporting also frames the issue as a “bias” in medical research, suggesting that the lack of representation can lead to evidence that is less applicable to local health needs.
The AllAfrica article highlights the same theme, emphasizing that despite the scale of health challenges, Africa remains largely missing from the trial processes that guide clinical decision-making. Both sources focus on the consequences of that absence for how universal medical knowledge is built, pointing to the need for more inclusive trial participation and better alignment between research populations and the regions most affected by disease. The articles do not name specific trial examples but converge on the broad pattern of under-inclusion.
